Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

MEDLEY Opens Philippines Office to Support Global Growth

MANILA, Philippines, April 4, 2024 /PRNewswire/ -- Medley, Inc. (TSE: 4480) ("MEDLEY"), aJapan-based internet service company, opened its Philippine office in Bonifacio Global City (BGC), Taguig onApril 1st to support continued global growth. The opening of the new office and upcoming operation l...

2024-04-04 10:59 2878

MEDLEY Opens Philippines Office to Support Global Growth

YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility

GAITHERSBURG, Md., April 3, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2024-04-03 20:00 1534

Ascletis Announces Strategic Decisions on FXR agonist ASC42

HANGZHOU, China and SHAOXING, China, April 3, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today the strategic decisions on farnesoid X receptor (FXR) agonist ASC42. After thorough analysis of the Phase II trial data of ASC42 for primary biliary cholangitis (PBC) (...

2024-04-03 17:10 1094

Tianlong Participated in International Medical Congress of SCO Countries in Kyrgyzstan

BISHKEK, Kyrgyzstan, April 3, 2024 /PRNewswire/ -- The International Medical Congress of the SCO countries was held on 27-29 March inBishkek, Kyrgyzstan, under the theme "Innovations and technologies in the development of cardiology and non-communicable diseases in the countries of the Shanghai C...

2024-04-03 16:16 2042

Tianlong Participated in International Medical Congress of SCO Countries in Kyrgyzstan

Great Place To Work unveils Top 10 Best Workplaces in Singapore Healthcare and Biopharma™ 2024

SINGAPORE, April 3, 2024 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture announcedSingapore's top 10 Best Workplaces in Healthcare and Biopharma™ in 2024.

2024-04-03 12:00 1988

RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome

YANTAI, China, April 3, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, obtained Fast Track Designation (FTD) by the United States Food and Drug Administration (FDA) recently for its inno...

2024-04-03 11:14 1512

Latvian pharmaceutical manufacturing company Grindeks opens new subsidiaries worldwide

RIGA, Latvia, April 3, 2024 /PRNewswire/ -- The leading pharmaceutical company in the Baltics, Grindeks, is developing new products and reinforcing its position not only in European but also global markets. With determination and innovative approaches, Grindeks continues to enhance the competitiv...

2024-04-03 05:00 1744

Latvian pharmaceutical manufacturing company Grindeks opens new subsidiaries worldwide

GC Cell to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

YONGIN, South Korea, April 2, 2024 /PRNewswire/ -- GC Cell , a fully integrated cell therapy pioneer has announced poster presentations from studies of its preclinical study of GL205 (GCC2005), a CD5 CAR-NK targeting malignant T-cell lymphoma, and real-world data f...

2024-04-02 23:00 1716

GC Cell to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH

SHANGHAI, April 2, 2024 /PRNewswire/ -- YolTech Therapeutics announced that the first patient has been dosed with YOLT-101, the company'sin vivo genome editing candidate being developed as a single dose, potentially curative therapy for Familial Hypercholesterolemia(FH), marking the commencement ...

2024-04-02 20:00 1074

CONCEPT MEDICAL RECEIVES US FDA IDE APPROVAL FOR MAGICTOUCH AVF INDICATION, THEIR FIFTH US CLINICAL STUDY APPROVAL FOR THE MAGICTOUCH PORTFOLIO

TAMPA, Fla., April 2, 2024 /PRNewswire/ -- Concept Medical has been granted 'IDE Approval' from the U.S. Food and Drug Administration (FDA) for MagicTouch AVF, its Sirolimus drug-coated balloon (DCB) catheter, to initiate a clinical study for the treatment of stenotic lesions of Arteriovenous Fis...

2024-04-02 17:33 2028

CONCEPT MEDICAL RECEIVES US FDA IDE APPROVAL FOR MAGICTOUCH AVF INDICATION, THEIR FIFTH US CLINICAL STUDY APPROVAL FOR THE MAGICTOUCH PORTFOLIO

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status

ROCKVILLE, Md. and SUZHOU, China, April 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune,...

2024-04-02 13:00 1800

Fosun International: Total Revenue for 2023 Reached RMB198.2 billion, Industrial Operation Profit Increased by 20% YoY

HONG KONG and SHANGHAI, April 2, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today announced its annual results for the year ended31 December 2023 (the "Reporting Period"). During the R...

2024-04-02 11:31 2934

23WELL, THE health supplement brand on the watch

LOS ANGELES, April 1, 2024 /PRNewswire/ -- Just earlier last month, the highly anticipated Natural Products Expo West 2024 concluded successfully inAnaheim, CA. As one of the world's largest leading health and nutrition exhibition, it hosted more than 65,000 registered attendees and 3,000+ exhibi...

2024-04-02 09:07 1407

Aculys Pharma Announces Appointment of Hidemasa Tanigaki as New CEO

～Hidemasa's appointment bolsters Aculys' position as a leader in the field of CNS inJapan and Asia～ TOKYO, April 1, 2024 /PRNewswire/ -- Aculys Pharma, Inc. ("Aculys"), a clinical-stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, today ...

2024-04-01 14:30 1321

LISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8 for the treatment of primary sclerosing cholangitis (PSC)

* Phase 2 study is underway and LB-P8 is the only live biotherapeutic product currently reported to be in clinical development for the treatment of PSC * FDA's Fast Track designation for LB-P8 underlines the urgent need for treatment options to fulfill the unmet medical needs of people affecte...

2024-03-29 21:00 2311

73% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis

SAN FRANCISCO, March 29, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that their cor...

2024-03-29 20:40 1823

Alebund's Innovative Investigational Drug AP303 Receives FDA Orphan Drug Designation (ODD) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SHANGHAI, March 29, 2024 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced today that th...

2024-03-29 20:00 1483

IASO Bio Announces NMPA's IND Approval for Equecabtagene Autoleucel in Second- and Third-Line Treatment of Multiple Myeloma

SHANGHAI and NANJING, China and SAN JOSE, Calif., March 29, 2024 /PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced thatChina National Medical Products Administratio...

2024-03-29 17:20 1319

Alphamab Oncology Reports Full Year 2023 Financial Results and Business Highlights

SUZHOU, China, March 29, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year endedDecember 31, 2023 and highlighted recent progress and upcoming milestones. Dr. Ting Xu, Chairman and CEO of Alphamab Oncology, commented, "In 2023, Alphamab Onc...

2024-03-29 10:42 7729

Jacobio Pharma Announces 2023 Annual Results

BEIJING, SHANGHAI and BOSTON, March 28, 2024 Jacobio/PRNewswire/ -- Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue wasRMB63.5 million, the R&D investment wasRMB372 million, the cash and cash equivalent at...

2024-03-29 08:50 3890

1 234 5 6 ... 292